Advanced search
1 file | 1.07 MB Add to list

Blood eosinophil levels as a biomarker in COPD

(2018) RESPIRATORY MEDICINE. 138. p.21-31
Author
Organization
Abstract
Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder and patients respond differently to treatment. Blood eosinophils are a potential biomarker to stratify patient subsets for COPD therapy. We reviewed the value of blood eosinophils in predicting exacerbation risk and response to corticosteroid treatment in the available literature (PubMed articles in English; keywords: "COPD" and "eosinophil"; published prior to May 2017). Overall, clinical data suggest that in patients with a history of COPD exacerbations, a higher blood eosinophil count predicts an increased risk of future exacerbations and is associated with improved response to treatment with inhaled corticosteroids (in combination with long-acting bronchodilator[s]). Blood eosinophils are therefore a promising biomarker for phenotyping patients with COPD, although prospective studies are needed to assess blood eosinophils as a biomarker of corticosteroid response for this.
Keywords
OBSTRUCTIVE PULMONARY-DISEASE, RANDOMIZED CONTROLLED-TRIAL, PLACEBO-CONTROLLED TRIAL, INHALED CORTICOSTEROIDS, AIRWAY INFLAMMATION, SPUTUM EOSINOPHILIA, CHRONIC-BRONCHITIS, DOUBLE-BLIND, SALMETEROL/FLUTICASONE PROPIONATE, HOSPITALIZED EXACERBATIONS, Eosinophils, COPD, Corticosteroids, Exacerbations

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.07 MB

Citation

Please use this url to cite or link to this publication:

MLA
Brusselle, Guy, Ian D Pavord, Sarah Landis, et al. “Blood Eosinophil Levels as a Biomarker in COPD.” RESPIRATORY MEDICINE 138 (2018): 21–31. Print.
APA
Brusselle, G., Pavord, I. D., Landis, S., Pascoe, S., Lettis, S., Morjaria, N., Barnes, N., et al. (2018). Blood eosinophil levels as a biomarker in COPD. RESPIRATORY MEDICINE, 138, 21–31.
Chicago author-date
Brusselle, Guy, Ian D Pavord, Sarah Landis, Steven Pascoe, Sally Lettis, Nikhil Morjaria, Neil Barnes, and Emma Hilton. 2018. “Blood Eosinophil Levels as a Biomarker in COPD.” Respiratory Medicine 138: 21–31.
Chicago author-date (all authors)
Brusselle, Guy, Ian D Pavord, Sarah Landis, Steven Pascoe, Sally Lettis, Nikhil Morjaria, Neil Barnes, and Emma Hilton. 2018. “Blood Eosinophil Levels as a Biomarker in COPD.” Respiratory Medicine 138: 21–31.
Vancouver
1.
Brusselle G, Pavord ID, Landis S, Pascoe S, Lettis S, Morjaria N, et al. Blood eosinophil levels as a biomarker in COPD. RESPIRATORY MEDICINE. 2018;138:21–31.
IEEE
[1]
G. Brusselle et al., “Blood eosinophil levels as a biomarker in COPD,” RESPIRATORY MEDICINE, vol. 138, pp. 21–31, 2018.
@article{8570024,
  abstract     = {Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder and patients respond differently to treatment. Blood eosinophils are a potential biomarker to stratify patient subsets for COPD therapy. We reviewed the value of blood eosinophils in predicting exacerbation risk and response to corticosteroid treatment in the available literature (PubMed articles in English; keywords: "COPD" and "eosinophil"; published prior to May 2017). Overall, clinical data suggest that in patients with a history of COPD exacerbations, a higher blood eosinophil count predicts an increased risk of future exacerbations and is associated with improved response to treatment with inhaled corticosteroids (in combination with long-acting bronchodilator[s]). Blood eosinophils are therefore a promising biomarker for phenotyping patients with COPD, although prospective studies are needed to assess blood eosinophils as a biomarker of corticosteroid response for this.},
  author       = {Brusselle, Guy and Pavord, Ian D and Landis, Sarah and Pascoe, Steven and Lettis, Sally and Morjaria, Nikhil and Barnes, Neil and Hilton, Emma},
  issn         = {0954-6111},
  journal      = {RESPIRATORY MEDICINE},
  keywords     = {OBSTRUCTIVE PULMONARY-DISEASE,RANDOMIZED CONTROLLED-TRIAL,PLACEBO-CONTROLLED TRIAL,INHALED CORTICOSTEROIDS,AIRWAY INFLAMMATION,SPUTUM EOSINOPHILIA,CHRONIC-BRONCHITIS,DOUBLE-BLIND,SALMETEROL/FLUTICASONE PROPIONATE,HOSPITALIZED EXACERBATIONS,Eosinophils,COPD,Corticosteroids,Exacerbations},
  language     = {eng},
  pages        = {21--31},
  title        = {Blood eosinophil levels as a biomarker in COPD},
  url          = {http://dx.doi.org/10.1016/j.rmed.2018.03.016},
  volume       = {138},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: